Pharmaceuticals Model Launched

WPP-owned healthcare and pharmaceutical market research specialist Ziment has introduced COMPOUNDZ, a system for modeling the potential uptake of new products.

The company says the new approach leverages its industry-standard operations alongside its advanced decision-modeling capabilities to halve the time previously required to project sales. COMPOUNDZ allows manufacturers to measure likely uptake of a wide variety of possible new products within the limits of the due diligence process.

'Distinguishing winning compounds from among the thousands evaluated by pharmaceutical companies every year is a high-stakes game' says CEO John Tapper. 'Traditionally, key market feedback was gathered using qualitative research alone. Now, using COMPOUNDZ, our clients are able to bring rigorous, projectable techniques to reduce the risks inherent in these decisions.'

'COMPOUNDZ gives clients tremendous freedom to test the key attributes that may drive uptake, especially when making high-stakes go/no-go decisions' according to Chief Methodologist Josh Rossol. 'There are some boundaries on complexity, but clients can test everything that really matters at this early stage - and they can make the decisions they need to make with confidence.'

Ziment is online at www.ziment.com . A month ago, the company introduced an analytic technique for modelling 'order-of-entry' effects on new product research and forecasting.

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Ziment Group
• All news